Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations by Sheridan, Graham & Dev, Kumlesh K.
Targeting S1P receptors in experimental
autoimmune encephalomyelitis in mice
improves early deficits in locomotor
activity and increases ultrasonic
vocalisations
Graham K. Sheridan* & Kumlesh K. Dev
Drug Development, School of Medicine, Trinity College Dublin, Dublin, Ireland.
Fingolimod (FTY720) is an oral therapy for relapsing remitting multiple sclerosis (MS) and targets
sphingosine 1-phosphate receptors (S1PRs). FTY720 also rescues animals from experimental autoimmune
encephalomyelitis (EAE), an animal model of MS. The protective effects of FTY720 in EAE are primarily
scored manually by examining weight loss and limb paralysis that begins around 10–12 days after
immunisation. To our knowledge, pre-clinical effects of FTY720 on animal behaviour early in EAE have not
been explored. Here, we developed an automated behaviour monitoring system to examine the early effects
of FTY720 on subtle pre-symptomatic behaviour of mice induced with EAE. Our automated home-cage
monitoring system (AHC-MS) enabled non-contact detection of movement and ultrasonic vocalisations
(USVs) of mice induced with EAE, thus allowing detection of subtle changes in mouse behaviour before
paralysis occurs. Mice receiving FTY720 emit longer USVs and display higher levels of motor activity than
vehicle-treated EAEmice before clinical symptoms become apparent. Importantly, this study promotes the
3Rs ethics (replacement, reduction and refinement) in the EAE animal model and may also improve
pre-screening of potentially novel MS therapies. In addition, this is the first report showing the early effects
of FTY720 in EAE which underscores its protective effects.
T
he family of sphingosine 1-phosphate receptors (S1PRs) is G-protein coupled and comprises the subtypes
S1P1–5R1–3. The oral therapy for relapsing-remitting multiple sclerosis (MS), called fingolimod (FTY720),
regulates S1PRs making these receptors bona fide drug targets for this illness4,5. S1PRs are expressed in a
number of cell types such as those of the immune and central nervous systems2,3. The phosphorylated version of
FTY720 (pFTY720) works by internalising the S1P1R subtype in T cells, limiting their cellular migration along
S1P gradients, egress from lymphoid organs and thus entry into the CNS6–10. S1P1Rs on endothelial cells are also
thought to tighten the blood brain barrier (BBB), in response to pFTY720, likely further restricting T cell
movement into the CNS11,12. Moreover, pFTY720 regulates cytokine release and antibody production from
immune cells, which likely contributes to its protective effects in MS13–15. Importantly, lipophilic FTY720 readily
crosses the BBB where it is phosphorylated to pFTY720 and activates S1PRs expressed in neuronal and glial
cells16–18. Mounting evidence suggests that pFTY720 can directly alter S1PRs function in these brain cells, which
may also be part of this drug’s mechanism-of-action in MS2,19–24.
The animal model that is considered to most closely model multiple sclerosis is termed experimental
autoimmune encephalomyelitis (EAE)25–28. EAE is thought to, in some aspects, replicate MS in terms of the
inflammation and ensuing CNS demyelination29,30. This animal model is induced by delivering an antigenic
myelin-derived peptide along with an adjuvant that together initiate an inflammatory response producing
autoreactive lymphocytes that target the host’s endogenous myelin31. Usually, over the course of 10–12 days,
the animal’s immune system attacksmyelin and the subsequentmotor deficits can be quantified by a standardised
manual scoring system that rates the severity of the disease at various stages: no disease (score 0), complete limp
tail (score 1), mild, moderate and complete hind limb paralysis (scores 2, 3 and 4, respectively), front limb
paralysis and incontinence (score 5), and finally a moribund state (score 6)32. While this scoring system is
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commonly used, those in the field generally note that inherent vari-
ability between researchers can occur using this approach33. Daily
handling can also affect experimental results34, for example where
stress can raise corticosterone levels in animals, which can alter EAE
disease progression35–38. Furthermore, using this clinical scoring sys-
tem, animals generally reach high disease scores before the beneficial
effects of therapies can be assessed39,40.
Studies show that prophylactic administration of FTY720 reduces
the severity of EAE if given from day 0 of EAE induction and also
improves motor symptoms if therapeutically administered at the
peak of EAE pathology21,41–47. A major advantage of FTY720 is that
it can be administered orally48,49 thus minimising the need of daily
injections or stressful gavage regimens. In this study, we describe an
automated home-cage monitoring system (AHC-MS) that can be
used to track locomotion and record ultrasonic vocalisations
(USVs) of mice in their home-cage environment. This system was
used to detect, in an automated non-contact manner, subtle motor
and behavioural abnormalities in EAE mice before the onset of clin-
ical symptoms. We also assess the effects of FTY720 on pre-symp-
tomatic motor and behavioural parameters in EAE mice to validate
this model system and further examine the early effects of FTY720 in
EAE.
Results
FTY720-treated EAE mice show preference for active behaviours
compared to vehicle controls. In order to investigate the general
behaviour of mice induced with EAE, the percentage of time spent in
each quadrant of the home-cage (Figure 1A) was calculated over a
three day baseline period prior to induction of EAE (days -3 to -1)
(Figure 1B). There was remarkable consistency in the times spent in
each quadrant between the two groups of mice during this baseline
period (Figure 1B). Control EAEmice spent 45.46 2.1% of their time
in quadrant 3 (Nest Zone) prior to EAE induction, where they
presumably spent a large proportion of that time asleep, compared
to 46.1 6 0.3% for FTY720-treated mice. The duration spent in the
Nest Zone did not vary significantly between vehicle control and
FTY720-treated mice over the course of EAE disease progression
(Figure 1B, Nest Zone). The vehicle control EAE group did,
however, spend significantly longer in the Nest Zone on days 4–6
post-EAE induction (59.36 5.3%) compared to their baseline period
(two-way ANOVA; p value , 0.05) (Figure 1B, Nest Zone). There
was also a dramatic decrease in the percentage of time spent in
quadrant 4 (Water Zone) in both vehicle control and FTY720-
treated groups post-EAE induction (20.9 6 0.9% vs. 11.2 6 2.1%
and 22.5 6 1.2% vs. 10.8 6 2.4%, respectively; two-way ANOVA; p
value, 0.05) (Figure 1B,Water Zone). The time spent in the Water
Zone recovered toward baseline levels for both vehicle control and
FTY720-treated EAE mice on days 7–9, with the FTY720 treated
mice showing a significantly better recovery than vehicle control
animals (Figure 1B, Water Zone). On days 7–9 post-EAE induction
there was also a statistically significant difference in the amount of
time each group spent in quadrant 1 (Straw Zone) between vehicle
control and FTY720-treated EAE animals (12.3 6 1.8% vs. 23.0 6
3.9%) (Figure 1B, Straw Zone) and quadrant 2 (Tissue Roll) (20.5 6
1.4% vs. 10.3 6 0.1%) (Figure 1B, Tissue Roll Zone). The mice in
quadrant 2 were generally found hiding inside the tissue roll and thus
Figure 1 | General activity behaviours in EAE mice treated with or
without FTY720. (A) Automated Home Cage Monitoring System (AHC-
MS). PhenoTyperH home-cages (Noldus) were fitted with top-view
camera and infrared LED illumination, EthovisionTM XT tracking software
(Noldus) and USV ‘bat recorder’ microphone. The EthovisionTM XT
tracking software allowed for the demarcation of the home-cage into 4
distinct quadrants. Quadrant 1 contained straw which the mice used to
burrow and dig in. Quadrant 2 contained a tissue roll which served as an
object the animals could explore and hide in. Quadrant 3 contained the
nest which the animals used to sleep in and huddled close together to stay
warm. Quadrant 4 contained the drinking water tap supplemented with or
without 2 mg/ml FTY720, which the mice received from day 0, i.e. day of
EAE induction. Home-cages housed 5 mice induced with EAE. They
received ad libitum access to food and water. The image/diagram was
created by the co-authors (GKS, KKD). (B) Total time spent in each
quadrant. The percentage of time the mice spent in each quadrant was
calculated overnight (16 hours) between 18:00h–10:00h. The average of
days -3 to -1 (i.e. beforeMOG35-55 peptide1CFA subcutaneous injection)
was taken as the control baseline and was almost identical for both groups
of mice. The averages of days 0–3 and days 4–6 showed no statistically
significant differences between control EAE and EAE 1 FTY720 treated
mice. At days 7–9, however, there was a statistically significant difference in
the percentage of time spent in quadrant 4 bymice who received FTY720 in
their drinking water. EAE mice receiving FTY720 also showed a higher
preference for quadrant 1, and a lower preference for quadrant 2 compared
to EAE mice not receiving FTY720. This indicates a preference for active
behaviours, such as burrowing and digging, over more passive behaviours,
such as exploring and hiding, in mice receiving the anti-inflammatory
drug, FTY720. *5 statistical significance based on amultiple comparisons
Student’s t test using the Holm-Sidak correction method with an alpha
value of 0.05.
www.nature.com/scientificreports
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engaged in relatively passive behaviours (Figure 1B, Tissue
Roll Zone). In contrast, the mice in quadrant 1 were foraging,
burrowing and gathering nesting material thus displaying more
active behaviours. Therefore, compared to vehicle control, the
mice receiving FTY720 appeared generally more active suggesting
early beneficial effects of FTY720 in EAE.
FTY720 treatment improves locomotor activity in mice at early
EAE stages. In addition to the altered times spent in the four
quadrants between vehicle control and FTY720-treated EAE mice,
we also found a reduction in the distance travelled by EAEmice in the
first 4 days post-EAE induction for both vehicle control (52.0 6
10.2%) and FTY720-treated (54.7 6 14.0%) groups (Figure 2A).
Likewise, the velocity at which the mice moved in these first 4 days
was also reduced for vehicle control (79.5 6 0.8%) and FTY720-
treated (77.5 6 0.8%) groups (Figure 2B). This significant
reduction in activity 4 days post-EAE induction is likely due to a
moderate amount of pain, irritation and anxiety caused by the sub-
cutaneous and intra-peritoneal injections of MOG35–55/CFA and
pertussis toxin. Notably, mice treated with FTY720 made a faster
recovery and, on days 4–9 post-EAE induction, showed statistically
significant increases in the distances travelled (54.56 4.4% vs. 69.26
0.8% on days 4–6 and 79.8 6 1.7% vs. 96.5 6 3.3% on days 7–9)
(Figure 2A) and their speed of movement (82.9 6 0.6% vs. 103.6 6
0.7% on days 4–6 and 95.2 6 0.9% vs. 111.9 6 1.0% on days 7–9)
(Figure 2B) around the cage compared to vehicle control
counterparts.
FTY720-treated EAE mice emit longer USVs than vehicle control
EAE mice. We next measured collective USV events (50 kHz)
emitted by each group of mice over the 12 day time-course of the
experiment. There was no statistically significant change from
baseline in the number of USVs emitted by either vehicle control
or FTY720-treated group post-EAE induction (Figure 3A). Likewise,
there were no significant differences in the number of events between
vehicle control and FTY720-treated EAE mice (Figure 3A). The
total duration of USV events was, however, significantly longer in
FTY720-treated EAEmice compared to vehicle control EAEmice on
days 4–6 post-EAE induction (Figure 3B). This difference was due to
an increase in the mean duration of each USV event in FTY720-
treated mice (138.5 6 15.3% of baseline duration) (Figure 3C).
The mean duration of each USV event increased even further to
145.6 6 15.7% of the baseline on days 7–9 post-EAE induction in
FTY720-treated mice (Figure 3C). In contrast, the mean duration of
USV events remained relatively constant in control EAE mice over
the course of the disease (Figure 3C). This suggests, therefore, that
EAE does not alter mean 50 kHz USV duration. FTY720 treatment,
on the other hand, increases mean USV duration. Whether this is an
indication of increased social interaction in FTY720-treated mice
compared to drug-free controls remains to be confirmed.
Discussion
At present, pre-clinical evaluation of potential therapeutics for MS is
generally determined by investigating their effectiveness in preventing/
treating EAE, an animal model of MS. The symptomatology in EAE
requires 10–12 days to manifest and the motor impairments are quan-
tified manually using a standardised scoring system. Our aim, in this
study, was to develop an automated system with the ability to detect
pre-symptomatic abnormalities in locomotion and behaviour in mice
before the overt motor disabilities of EAE emerged. To achieve this, we
used a well characterised protocol where C57BL/6 mice were induced
with a chronic progressive form of EAE using the MOG35–55 peptide
as the antigen50,51. We also developed an automated home-cage mon-
itoring system (AHC-MS) that was able to detect subtle motor impair-
ments in mice earlier than a manual scoring method. This AHC-MS
had the following notable features: 1) it allowed visual recording and
tracking, in real-time, of animal locomotion in their home-cage envir-
onment, 2) it had a large enriched environment to promote more
natural animal behaviours such as exploration, foraging, burrowing
and nest-building activities, which could also be monitored remotely,
3) it minimised handling of animals, thus potentially reducing anxiety
and stress, 4) it allowed animals to be monitored for long periods
overnight when they are at their most active, 5) it recorded collective
USVs of mice, and 6) it minimised unintentional experimenter bias
via automated recordings.
In order to validate this AHC-MS as an effective screening plat-
form for MS therapeutics, we assessed the effects of the oral drug,
FTY720, on the early stages of EAE inmice. All mice weremonitored
for 10 days post-immunisation with MOG35–55 and maintained a
clinical score of 0 for the duration of the experiment. Pre-symp-
tomatic abnormalities in locomotion and USVs were analysed in
vehicle- versus FTY720-treated EAE mice. Our results confirmed
the protective effects of FTY720 on EAE-induced motor deficits
Figure 2 | Locomotor activity in control EAE mice treated with or
without FTY720. (A) Distances travelled. The average distances travelled
by the mice each day were calculated and the baseline was taken as the
average of days -3 to -1. This value was set to 100% for each group of mice
and the subsequent deviations in distance travelled post-EAE induction
were calculated as a percentage of the baseline. The locomotor activity of
the mice drastically reduced over the first 4 days after EAE induction in all
mice. The mice treated with FTY720 showed a significantly quicker
recovery time toward baseline values over the subsequent 6 days compared
to the mice that received no drug. (B) Velocities of movements. The
baseline was set to 100% and was calculated based on the average of the
velocity of movement 3 days before EAE induction (days -3 to -1). There
was a significant reduction in the velocity ofmovement over the first 4 days
post-EAE induction in all mice. The mice treated with FTY720 recovered
their locomotion speed quicker than control EAE mice over the
subsequent 6 days. * 5 statistical significance based on a multiple
comparisons Student’s t test using the Holm-Sidak correction method
with an alpha value of 0.05.
www.nature.com/scientificreports
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and demonstrated beneficial effects of the drug up to one week prior
to clinical symptomatology onset; far sooner than previous studies
have detected.We found, compared to vehicle-treated EAEmice, the
FTY720-treated EAE mice displayed a preference for active beha-
viours including foraging, burrowing and gathering nestingmaterial.
Drug-treated mice also displayed greater locomotor activities,
namely, distance travelled and speed of movement. Interestingly,
EAE induction did not alter the number or the duration of group
USVs emitted during the early disease period. However, FTY720-
treated EAEmice emitted USVs of longer duration on days 4–6 post-
EAE induction. This increase in USV duration coincided with an
increase in locomotor activity in FTY720-treated EAE mice and
may also correspond to an increase in social interaction, since
FTY720-treated mice spent more time burrowing, exploring and
nest-building 7–9 days post-EAE induction. These vocalisations
appeared to also associate with increased activity in mice since they
directly correlated with a return-to-baseline of normal velocity and
distance travelled post-EAE.
At this stage, we cannot rule out a direct or indirect CNS-based
pharmacological mechanism underlying the increasedUSVduration
recorded in FTY720-treated mice. It has previously been shown that
some pharmacological treatments can alter USVs in rodents. For
example, morphine has been demonstrated to reduce 50 kHz
USVs52, whereas the GABAA receptor antagonist, pentylenetetrazol,
can cause an increase in USVs in rats53. Therefore, FTY720 may
increase 50 kHz USVs in mice through pharmacological actions
on S1PRs in the CNS and/or in other systems where S1PRs are
expressed. In addition, it is worth noting that environmental enrich-
ment has been observed to increase USVs in rodents54 and that
emission of 50 kHz vocalisations correlates with positive affect in
rats55,56, although their function in mice is less clearly defined57.
Moreover, vocal communications between female mice in the 50–
70 kHz frequency range have been positively correlated with various
social interaction situations58. It is tempting to attribute FTY720’s
increase in mean USV event duration described here with a more
positive emotional state and increased social communication among
group-housed female mice. However, interpreting the physiological
and emotional meaning of USVs in mice, in particular, is still
controversial.
Previous studies have shown that behavioural and emotional stress
in rodents can sometimes inhibit or accelerate EAE disease progres-
sion, depending on the timing and duration of the stressor35–38;
where, for example, over-activation of the hypothalamic-pituitary-
axis (HPA) through raised corticosterone levels can suppress immune
function. The administration of FTY720 to animals in drinking water
results in similar therapeutic responses in EAE compared to daily i.p.
injections of drug48,49. We thus took advantage of FTY720’s capacity
to be administered via the drinking water and used it, at a similar
concentration to that suggested by previous studies, in our AHC-
MS48,49. We therefore avoided daily intra-peritoneal injections or oral
gavage allowing reduced handling and stress associated with these
drug administration methods. Notably, there was no difference in the
volume of water consumed per day by vehicle- and FTY720-treated
groups of EAEmice (approx. 15 ml/group/day) over the course of the
disease.
Overall, this study is a proof-of-principle that the developed AHC-
MS is sensitive to early pre-symptomatic motor deficits in mice with
EAE. It also demonstrates the early protective effects of FTY720.
While it will be necessary to assess the effects of other anti-inflam-
matory compounds, also known to be beneficial in EAE, this system
has the potential to improve experimental methods associated with
manual clinical scoring. We do not see this AHC-MS as a complete
replacement to the current clinical scoring methods, but rather an
additional tool that can be used alongside gold standard routines to
assess beneficial drug responses in EAE. The most sensitive para-
meter describing FTY720’s therapeutic effects in the early phase of
Figure 3 | USVs in control EAE and EAE 1 FTY720 treated mice.
(A) Number of USVs (50 kHz), per hour. The baseline number of USV
events was set at 100% for each group of mice and calculated as the average
of the total number of events each day, three days before EAE induction
(days -3 to -1). There were no significant changes over the course of EAE
progression in the number of USVs from either control EAE or EAE 1
FTY720 treated mice. (B) Total Duration of USVs (50 kHz). The total
duration the mice spent emitting USVs decreased significantly in control
EAE mice post-EAE induction but returned to baseline levels 7–9 days
post-immunisation. There was a statistically significant difference in the
total duration of USVs between control and FTY720-treated mice on days
4–6 post-EAE induction. (C) Mean Duration of each 50 kHz USV. The
mean duration of each individual USV event did not vary significantly
from the baseline in control EAEmice. Mice induced with EAE and treated
with FTY720, however, showed a statistically significant increase in the
mean duration of each USV event on days 4–6 and days 7–9 post-EAE. The
mean duration of each event also differed significantly from control EAE
mice on days 4–6 post-EAE. *5 statistical significance based on amultiple
comparisons Student’s t test using the Holm-Sidak correction method
with an alpha value of 0.05.
www.nature.com/scientificreports
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EAEwas the return-to-baseline in the animal’s velocity of movement
on days 4–6 post-immunisation. It would be important when testing
other drugs for potential therapeutic benefit in EAE, to assess if they
also exert similar improvements in animal locomotion at these early
stages post-EAE induction. An important advantage of this AHC-
MS is its versatility. The home-cage can be easily modified to detect
alterations in different types of animal behaviour. For example, novel
and familiar objects could be placed into the home-cage each day to
assess the effects of drugs on memory impairment or reduced
motivation associated with EAE59. Moreover, the effects of drugs
on more complex motor tasks such as wheel-running or beam-walk-
ing onto elevated platforms could easily be implemented using this
system. An obvious disadvantage of our AHC-MS is the initial cost
involved in purchasing large automated home-cages; although it is
certainly feasible to build custom-designed home-cages using rela-
tively inexpensive materials and readily affordable video and audio
recording technology. Moreover, the space restrictions within stand-
ard animal facilities may restrict the number of home-cages that can
be monitored in parallel. Another limitation of this method is that
most pre-clinical compounds do not have as good oral bioavailability
as FTY720 and cannot be administered to mice through their drink-
ing water. Therefore, manual restraint and injection of test com-
pounds may be necessary in certain situations. The confounding
anxiogenic effects of these drug-delivery methods could be mini-
mised, however, by injecting the mice first thing each morning after
overnight video tracking is complete.
Finally, we believe this AHC-MS would also provide a means to
better satisfy the 3Rs ethical policy in animal research, i.e. replace-
ment, reduction and refinement60. Examining the effects of novel
compounds at these early time points in EAE should also shorten
experimental time-frames and may improve and broaden our mech-
anistic understanding of therapies used in MS.
Methods
Animal Care and Automated Home Cage Monitoring System (AHC-MS).
Postnatal day 60 C57BL/6 female mice (25–30 g) were obtained from Harlan and
housed in the Bioresources Unit, Trinity College Dublin, Ireland. All experimental
procedures were approved by the animal research ethics committee and head
veterinarian of the Bioresources Unit, TCD and were carried out by individuals who
held the appropriate license issued by the minister for health and children. The
methods were carried out in accordance with the approved guidelines. Animals were
socially housed in groups of 5 in standard laboratory cages, allowed to acclimatise to
the new facility for 5 days and given ad libitum access to food and water. The
experimental room was kept on a 12 h light/dark cycle at 22 6 2uC. Mice were then
transferred, in the same social groups, to the automated home-cage monitoring
system (AHC-MS), i.e. the commercially available PhenoTyperH home-cage (Noldus,
Wageningen, Netherlands) (Figure 1A). Themice were allowed to acclimatise to these
larger enriched environment cages for a further 5 days. The cage was demarcated into
four distinct quadrants. Quadrant 1 contained a large bundle of straw which was
added to enable the mice to enact their natural propensity to burrow, dig and nest-
build. A standard tissue roll was placed in Quadrant 2 which, in the beginning, served
as a novel object for the mice to explore but, after some time, the animals used it to
climb on and hide in. Quadrant 3 contained a red opaque plastic nest which the
animals used to sleep in and huddle close together to stay warm. Quadrant 4
contained the drinking-water tap which contained water either unsupplemented (i.e.
control EAE group) or supplemented with 2 mg/ml FTY720 (i.e. EAE 1 FTY720
group). Normal rodent chow was accessible through a large grill located close to the
floor of the cage and spanned quadrants 3 and 4. The roof of the PhenoTyperH cage
was approx. 60 cm from the cage floor (453 45 cm) and was fitted with infrared LED
lights and a wide field of view camera connected to an external computer running
EthovisionTM XT software (Noldus). The roof of the cage also housed an ultrasound
detector (Mini-3 bat model, connected to Ultravox software running on an external
PC) which was used to detect USVs in a specific frequency range. We tested several
frequency ranges from 40–80 kHz over the five day acclimatising period and found
USVs detected in the 50 kHz range delivered the largest and most consistent number
of events between cages. Since the bat recorder only allowed us to record within a
narrow frequency range, we chose 50 kHz as the optimal frequency to detect
throughout the whole experiment. After 5 days, the bedding of the cages was changed
and fresh food and water were added. Baseline measurements of locomotor activity
and USVs were then recorded for 3 days prior to EAE induction (i.e. days -3, -2, -1).
Recordings were conducted for 16 hours each day overnight from 18:00h to 10:00h.
This was to ensure that no other researchers or animal technicians would enter the
room and disturb the mice or recordings. Since the mice are nocturnal and mostly
sleep during the day, this allowed us to record them at their peak daily activity; which
remains a limiting paradigm for manual EAE scoring. The locomotion (i.e. speed and
distance travelled) was averaged each day and an average of the first 3 days was taken
as the ‘baseline’ for each group of animals. These baseline values were set to 100%.
Average daily variations in locomotor activity post-EAE induction for each group of
mice were compared to these baseline values.
MOG35 – 55 peptide EAE induction protocol and FTY720 administration. Mice
were immunised by sub-cutaneous injection (s.c.) of 100 mg MOG35–55 peptide
(GenScript) emulsified in Complete Freund’s Adjuvant (CFA) containing 4 mg/ml
(0.4 mg/mouse) of heat-inactivated M. tuberculosis (Chondrex). Mice were also
injected intra-peritoneal (i.p.) with 500 ng pertussis toxin (Kaketsuken) on days 0 and
2. This method has been shown to consistently induce a chronic progressive form of
EAE in 100% of immunised mice. This chronic EAE consists of a single peak in
symptomatology beginning around days 10–12 and shows maximal penetrance
around days 17–22 followed by a gradual (but incomplete) improvement in motor
symptoms from day 25 onwards61. In this study, animals were humanely euthanized
prior to motor deficit onset on day 9 post-EAE induction. In this way, we aimed to
develop a sensitive, automated and non-contact method for detecting early motor
impairments in EAE as well as devising an improved protocol for screening novel
drugs with the added advantage of reducing the numbers and suffering of laboratory
animals by implementing the 3Rs policy. Two groups of 5 mice were used in this
study, i.e. Control EAE and EAE 1 FTY720. The EAE 1 FTY720 group of mice
received ad libitum access to drinking water containing 2 mg/ml FTY720. The
Control EAE group received normal drinking water.
Data collection and statistical analysis. Locomotor activity was recorded directly
from the camera in the ceiling of the cage to an external PC using EthovisionTM XT
software (Noldus). USV events in the 50 kHz frequency band were recorded using a
bat detector microphone (Mini-3 bat model) and processed in real-time by Ultravox
software which saved the data onto the same external PC as 1) number of USV events,
2) total duration of events and 3) mean USV event duration. Recordings were
acquired each day for 16 hours between 18:00h and 10:00h overnight. Data was
collected in Microsoft Excel and imported into GraphPad Prism statistical software.
Data was analysed using either 1) multiple comparisons Student’s t test using the
Holm-Sidak correction method with an alpha value of 0.05; or 2) two-way ANOVA
with Tukey correction for multiple comparisons and p value , 0.05 indicating
significance.
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